



# FDA's Impact

## on pharmaceutical innovation



Please join us for a lecture by Neil Flanzraich, Chairman and CEO of Cantex Pharmaceuticals, Inc., discussing the balance between speed and safety in FDA's regulation of pharmaceutical products. Topics will include how FDA's approach has ebbed and flowed over time, the various tools FDA has introduced to reach this balance, and the potential impact of FDA's various approaches on products and companies, especially start-ups.

Neil Flanzraich graduated from Harvard Law School in 1968 and was appointed by Dean Martha Minow as an Expert in Residence at the Harvard Innovation Lab (i-lab) in fall 2012.

This event is free and open to the public. Lunch will be provided.

**Tuesday, April 14, 12:00pm**

**Griswold Hall 110, Harvard Law School**

**1525 Massachusetts Ave.**



Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

For more information, visit our website at <http://petrieflom.law.harvard.edu> or contact us at 617-496-4662 or [petrie-flom@law.harvard.edu](mailto:petrie-flom@law.harvard.edu).